AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
1. AbbVie presented Phase 2 EPCORE NHL-6 trial results for epcoritamab in DLBCL treatment. 2. Outpatient treatment showed low incidence of cytokine release syndrome and neurotoxicity. 3. The trial reported a 64.3% overall response rate among DLBCL patients. 4. Epcoritamab demonstrates potential to improve treatment access for blood cancer patients. 5. FDA approval for outpatient use is still pending for the first full dose.